| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802036101014 | 203610101 | SYSCOR F.C.TAB 5MG/TAB BTx30(BLIST3x10) | 5.29 | 5.55 | 7.65 |
| 05/2018 | 2802036103018 | 203610301 | SYSCOR CON.R.TAB 10MG/TAB BTx28(BLIST2x14) | 7.29 | 7.65 | 10.55 |
For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Relatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%.
7-12 hours
Although 60-80% of an oral dose undergoes urinary excretion, only traces of unchanged nisoldipine are found in urine.